statistiche ricercatore

Nazione	#
IT - Italia	10.788
US - Stati Uniti d'America	578
SG - Singapore	139
CN - Cina	125
SE - Svezia	77
BR - Brasile	44
DE - Germania	34
IN - India	28
FR - Francia	26
VN - Vietnam	25
CA - Canada	19
GB - Regno Unito	17
NL - Olanda	15
FI - Finlandia	14
HK - Hong Kong	14
KR - Corea	9
AT - Austria	8
PL - Polonia	8
IR - Iran	7
IQ - Iraq	6
AE - Emirati Arabi Uniti	5
ES - Italia	4
JP - Giappone	4
TH - Thailandia	4
VE - Venezuela	4
AR - Argentina	3
AU - Australia	3
BD - Bangladesh	3
GR - Grecia	3
IE - Irlanda	3
PK - Pakistan	3
RU - Federazione Russa	3
TR - Turchia	3
EC - Ecuador	2
IL - Israele	2
MA - Marocco	2
MX - Messico	2
NG - Nigeria	2
PH - Filippine	2
SA - Arabia Saudita	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
AL - Albania	1
AZ - Azerbaigian	1
BB - Barbados	1
BH - Bahrain	1
BO - Bolivia	1
CL - Cile	1
DZ - Algeria	1
HR - Croazia	1
ID - Indonesia	1
KG - Kirghizistan	1
LT - Lituania	1
LU - Lussemburgo	1
MN - Mongolia	1
MO - Macao, regione amministrativa speciale della Cina	1
PE - Perù	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
Totale	12.064

Nome	#
Molecular-biology-driven treatment for metastatic colorectal cancer	2.718
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment	1.308
Molecular-driven treatment for biliary tract cancer: the promising turning point	1.184
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors	1.006
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?	901
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment	816
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression	714
Uncovering key targets of success for immunotherapy in pancreatic cancer	680
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus	624
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials	621
BRCA-mutant pancreatic ductal adenocarcinoma	584
Immune Checkpoint Inhibitors in the Treatment of HCC	552
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	253
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients	153
Totale	12.114

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	431	0	0	0	0	0	120	40	64	35	70	49	53
2021/2022	1.147	53	48	3	25	40	84	56	120	69	95	188	366
2022/2023	2.498	275	375	260	167	184	233	115	157	164	292	182	94
2023/2024	1.946	79	56	80	107	166	354	365	160	97	97	186	199
2024/2025	4.934	1.486	1.641	403	463	209	319	214	26	37	51	31	54
2025/2026	630	130	82	105	116	96	101	0	0	0	0	0	0
Totale													12.114

UNICA IRIS Institutional Research Information System